FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W4285023345> ?p ?o ?g. }

• W4285023345 endingPage "104158" @default.
• W4285023345 startingPage "104158" @default.
• W4285023345 abstract "BackgroundIn recent months, Omicron variants of SARS-CoV-2 have become dominant in many regions of the world, and case numbers with Omicron subvariants BA.1 and BA.2 continue to increase. Due to numerous mutations in the spike protein, the efficacy of currently available vaccines, which are based on Wuhan-Hu 1 isolate of SARS-CoV-2, is reduced, leading to breakthrough infections. Efficacy of monoclonal antibody therapy is also likely impaired.MethodsIn our in vitro study using A549-AT cells constitutively expressing ACE2 and TMPRSS2, we determined and compared the neutralizing capacity of vaccine-elicited sera, convalescent sera and monoclonal antibodies against authentic SARS-CoV-2 Omicron BA.1 and BA.2 compared with Delta.FindingsAlmost no neutralisation of Omicron BA.1 and BA.2 was observed using sera from individuals vaccinated with two doses 6 months earlier, regardless of the type of vaccine taken. Shortly after the booster dose, most sera from triple BNT162b2-vaccinated individuals were able to neutralise both Omicron variants. In line with waning antibody levels three months after the booster, only weak residual neutralisation was observed for BA.1 (26%, n = 34, 0 median NT50) and BA.2 (44%, n = 34, 0 median NT50). In addition, BA.1 but not BA.2 was resistant to the neutralising monoclonal antibodies casirivimab/imdevimab, while BA.2 exhibited almost a complete evasion from the neutralisation induced by sotrovimab.InterpretationBoth SARS-CoV-2 Omicron subvariants BA.1 and BA.2 escape antibody-mediated neutralisation elicited by vaccination, previous infection with SARS-CoV-2, and monoclonal antibodies. Waning immunity renders the majority of tested sera obtained three months after booster vaccination negative in BA.1 and BA.2 neutralisation. Omicron subvariant specific resistance to the monoclonal antibodies casirivimab/imdevimab and sotrovimab emphasizes the importance of genotype-surveillance and guided application.FundingThis study was supported in part by the Goethe-Corona-Fund of the Goethe University Frankfurt (M.W.) and the Federal Ministry of Education and Research (COVIDready; grant 02WRS1621C (M.W.)." @default.
• W4285023345 created "2022-07-12" @default.
• W4285023345 creator A5001079546 @default.
• W4285023345 creator A5006586430 @default.
• W4285023345 creator A5020558938 @default.
• W4285023345 creator A5024349567 @default.
• W4285023345 creator A5026413966 @default.
• W4285023345 creator A5036983817 @default.
• W4285023345 creator A5038681888 @default.
• W4285023345 creator A5048918542 @default.
• W4285023345 creator A5053681765 @default.
• W4285023345 creator A5061641861 @default.
• W4285023345 creator A5064962021 @default.
• W4285023345 creator A5065285414 @default.
• W4285023345 creator A5071830053 @default.
• W4285023345 creator A5072311064 @default.
• W4285023345 creator A5087311831 @default.
• W4285023345 date "2022-08-01" @default.
• W4285023345 modified "2023-10-14" @default.
• W4285023345 title "Limited neutralisation of the SARS-CoV-2 Omicron subvariants BA.1 and BA.2 by convalescent and vaccine serum and monoclonal antibodies" @default.
• W4285023345 cites W1974569164 @default.
• W4285023345 cites W1989069389 @default.
• W4285023345 cites W2920688815 @default.
• W4285023345 cites W3001897055 @default.
• W4285023345 cites W3004280078 @default.
• W4285023345 cites W3009912996 @default.
• W4285023345 cites W3026002191 @default.
• W4285023345 cites W3036646301 @default.
• W4285023345 cites W3092403777 @default.
• W4285023345 cites W3096967708 @default.
• W4285023345 cites W3133782701 @default.
• W4285023345 cites W3133805672 @default.
• W4285023345 cites W3134446480 @default.
• W4285023345 cites W3135383916 @default.
• W4285023345 cites W3136570200 @default.
• W4285023345 cites W3138734145 @default.
• W4285023345 cites W3157661219 @default.
• W4285023345 cites W3164711393 @default.
• W4285023345 cites W3165479483 @default.
• W4285023345 cites W3170724610 @default.
• W4285023345 cites W3172858351 @default.
• W4285023345 cites W3176217635 @default.
• W4285023345 cites W3178509854 @default.
• W4285023345 cites W3194649867 @default.
• W4285023345 cites W3202903389 @default.
• W4285023345 cites W3211202897 @default.
• W4285023345 cites W4200047841 @default.
• W4285023345 cites W4200469371 @default.
• W4285023345 cites W4200488608 @default.
• W4285023345 cites W4205283268 @default.
• W4285023345 cites W4205331651 @default.
• W4285023345 cites W4205369318 @default.
• W4285023345 cites W4205728393 @default.
• W4285023345 cites W4206079892 @default.
• W4285023345 cites W4206135665 @default.
• W4285023345 cites W4206142017 @default.
• W4285023345 cites W4206693794 @default.
• W4285023345 cites W4206997616 @default.
• W4285023345 cites W4210272290 @default.
• W4285023345 cites W4210493562 @default.
• W4285023345 cites W4210604635 @default.
• W4285023345 cites W4210665241 @default.
• W4285023345 cites W4210708247 @default.
• W4285023345 cites W4220673385 @default.
• W4285023345 cites W4220729450 @default.
• W4285023345 cites W4220807057 @default.
• W4285023345 cites W4220886953 @default.
• W4285023345 cites W4220987557 @default.
• W4285023345 cites W4221072241 @default.
• W4285023345 cites W4221116249 @default.
• W4285023345 cites W4224324181 @default.
• W4285023345 cites W4225691034 @default.
• W4285023345 cites W4226087845 @default.
• W4285023345 cites W4226087910 @default.
• W4285023345 cites W4226090490 @default.
• W4285023345 cites W4226491433 @default.
• W4285023345 doi "https://doi.org/10.1016/j.ebiom.2022.104158" @default.
• W4285023345 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/35834885" @default.
• W4285023345 hasPublicationYear "2022" @default.
• W4285023345 type Work @default.
• W4285023345 citedByCount "110" @default.
• W4285023345 countsByYear W42850233452022 @default.
• W4285023345 countsByYear W42850233452023 @default.
• W4285023345 crossrefType "journal-article" @default.
• W4285023345 hasAuthorship W4285023345A5001079546 @default.
• W4285023345 hasAuthorship W4285023345A5006586430 @default.
• W4285023345 hasAuthorship W4285023345A5020558938 @default.
• W4285023345 hasAuthorship W4285023345A5024349567 @default.
• W4285023345 hasAuthorship W4285023345A5026413966 @default.
• W4285023345 hasAuthorship W4285023345A5036983817 @default.
• W4285023345 hasAuthorship W4285023345A5038681888 @default.
• W4285023345 hasAuthorship W4285023345A5048918542 @default.
• W4285023345 hasAuthorship W4285023345A5053681765 @default.
• W4285023345 hasAuthorship W4285023345A5061641861 @default.
• W4285023345 hasAuthorship W4285023345A5064962021 @default.
• W4285023345 hasAuthorship W4285023345A5065285414 @default.
• W4285023345 hasAuthorship W4285023345A5071830053 @default.
• W4285023345 hasAuthorship W4285023345A5072311064 @default.

• next